Lifecore Biomedical, Inc. LFCR
At closeNov 4, 2026, 5:07 PM EST
After hours · Nov 4, 5:07 PM ET
- YTD
- -21.27%
- 1 year
- -5.01%
- Market cap
- 244.11M
- Revenue (ttm)
- 128.44M
- Profit margin
- 5.09%
- EPS (ttm)
- -1.27
- Shares out
- 36.83M
- Forward P/E
- -9.90
- YTD return
- -21.27%
- 1-year return
- -5.01%
- Volume
- 270.72K
- Avg volume
- 385.03K
- Open
- 6.44
- Previous close
- 6.42
- Day's range
- 6.41 – 6.45
- 52-week range
- 3.63 – 8.98
- Beta
- 0.94
- Price target
- 8.00 (+24.2%)
- Earnings date
- Jan 2, 2025
2Y +0.29 (+4.72%)
Key statistics
- Enterprise value
- 398.49M
- PEG ratio
- 0.00
- Price / sales
- 2.02
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.70%
- Free cash flow
- -10.53M
- Total cash
- 5.52M
- Total debt
- 136.86M
- Return on equity
- 17.29%
- Short % of float
- 10.34%
- 50-day average
- 6.51
- 200-day average
- 5.84
Analyst view
- Target (low)
- 6.00
- Target (mean)
- 8.00
- Target (high)
- 10.00
- Strong buy0
- Buy1
- Hold2
- Sell0
- Strong sell0
Next earnings
Jan 2, 2025
Expected Jan 2, 2025. Consensus EPS estimate -0.305.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 2, 2025 | Nov 1, 2024 | -0.27 | — | — | — |
| Aug 26, 2024 | May 1, 2024 | 0.00 | -0.15 | — | — |
| Aug 9, 2024 | Feb 1, 2024 | 0.00 | -0.05 | — | — |
| Aug 9, 2024 | Nov 1, 2023 | 0.00 | -0.06 | — | — |
| Aug 9, 2024 | Aug 1, 2023 | 0.00 | -0.41 | — | — |
| Aug 31, 2023 | May 1, 2023 | -0.07 | -0.89 | -0.82 | -1,171.43% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 22, 2024 | Craig-Hallum | main | Buy | Buy |
| Sep 5, 2024 | Craig-Hallum | init | — | Buy |
| Aug 28, 2024 | Barrington Research | down | Outperform | Market Perform |
| Sep 1, 2023 | Barrington Research | main | Outperform | Outperform |
| Sep 1, 2023 | Stephens & Co. | main | Equal-Weight | Equal-Weight |
| Jun 2, 2023 | Barrington Research | main | Outperform | Outperform |
About Lifecore Biomedical, Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- lifecore.com
News
Lifecore Biomedical Q3 EPS $(1.08) Misses $(0.28) Estimate, Sales $25.322M Miss $26.699M Estimate 
Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update 
Are BWIN, LFCR, PCRX Obtaining Fair Deals for their Shareholders? 
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - LFCR, LSTA, FSHP and BWIN - IS IT A FAIR DEAL FOR YOU? 
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR) 
Lifecore Biomedical Q2 2026 Earnings Call Transcript 
Lifecore Biomedical to Participate at Upcoming Industry Conferences 
Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders? 
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD) 
EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- FWAC, MGLD, LFCR, and MG
Your note
Sign in to keep a note on LFCR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANTUNES HUMBERTO C | Director | Stock Award(Grant) | Aug 18, 2024 | 24,554 |
| ARYEH JASON M | Director | Stock Award(Grant) | Aug 18, 2024 | 24,554 |
| EDWARDS JEFFREY L | Director | Stock Award(Grant) | Jul 7, 2024 | 79,667 |
| HOUDE KATRINA LOVAS | Director | Stock Award(Grant) | Jul 7, 2024 | 89,906 |
| JOSEPHS PAUL | Chief Executive Officer | Stock Award(Grant) | Dec 5, 2024 | 542,717 |
| KIPER CHRISTOPHER S | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 2, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wynnefield Capital Management LLC | 13.36% | 4,918,979 | 34.58M | Sep 29, 2024 |
| Legion Partners Asset Management, LLC | 8.06% | 2,968,409 | 20.87M | Sep 29, 2024 |
| Greenhaven Road Investment Management, L.p. | 6.05% | 2,228,784 | 15.67M | Sep 29, 2024 |
| 22NW, LP | 4.77% | 1,755,161 | 12.34M | Sep 29, 2024 |
| Blackrock Inc. | 4.11% | 1,512,946 | 10.64M | Sep 29, 2024 |
| 325 Capital Llc | 3.72% | 1,369,785 | 9.63M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.11% | 775,941 | 5.45M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.31% | 480,764 | 3.38M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.99% | 363,800 | 2.56M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.58% | 212,895 | 1.50M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.52% | 191,330 | 1.35M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 164,047 | 1.15M | Oct 30, 2024 |